Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation

Current Cardiology Reports

Volumn 12, Issue 2, 2010, Pages 133-139

  Baber, Usman ^a   Van Der Zee, Sarina ^a   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Mechanical heart valves

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN A; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MEGADOSE; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART VALVE BIOPROSTHESIS; HEART VALVE PROSTHESIS; HEART VALVE SURGERY; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; MONITORING; MONOTHERAPY; PREGNANCY; REVIEW; RISK FACTOR; SELF MONITORING; STROKE; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; VALVULAR HEART DISEASE;

AGE FACTORS; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ATRIAL FIBRILLATION; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; RISK FACTORS; STROKE VOLUME; THROMBOEMBOLISM; VITAMIN K;

EID: 77953538367     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0085-x     Document Type: Review

References (45)

1. Carapetis JR, Currie BJ, Mathews JD: Cumulative incidence of rheumatic fever in an endemic region: A guide to the susceptibility of the population? Epidemiol Infect 2000, 124:239-244.
2. Cannegieter SC, Rosendaal FR, Briet E: Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994, 89:635-641.
3. Butchart EG, Lewis PA, Kulatilake EN, Breckenridge IM: Anticoagulation variability between centres: Implications for comparative prosthetic valve assessment. Eur J Cardiothorac Surg 1988, 2:72-81.
4. Yoganathan AP, He Z, Casey Jones S: Fluid mechanics of heart valves. Annu Rev Biomed Eng 2004, 6:331-362.
5. Butany J, Ahluwalia MS, Munroe C, et al.: Mechanical heart valve prostheses: Identification and evaluation. Cardiovasc Pathol 2003, 12:1-22. (Pubitemid 36206507)
6. Kulik A, Rubens FD, Wells PS, et al.: Early postoperative anticoagulation after mechanical valve replacement: A systematic review. Ann Thorac Surg 2006, 81:770-781. (Pubitemid 43120610)
7. Bonow RO, Carabello BA, Chatterjee K, et al.: 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008, 118:e523-e661.
8. Vahanian A, Baumgartner H, Bax J, et al.: Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007, 28:230-268.
9. Fanikos J, Tsilimingras K, Kucher N, et al.: Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol 2004, 93:247-250.
10. Montalescot G, Polle V, Collet JP, et al.: Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000, 101:1083-1086. (Pubitemid 30146606)
11. Cannegieter SC, Rosendaal FR, Wintzen AR, et al.: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995, 333:11-17.
12. Acar J, Iung B, Boissel JP, et al.: AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996, 94:2107-2112.
13. Butchart EG, Lewis PA, Bethel JA, Breckenridge IM: Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve. Circulation 1991, 84:III61-III69.
14. Hering D, Piper C, Bergemann R, et al.: Thromboembolic and bleeding complications following St. Jude Medical valve replacement: Results of the German Experience With Low-Intensity Anticoagulation Study. Chest 2005, 127:53-59. (Pubitemid 41724555)
15. Salem DN, O'Gara PT, Madias C, Pauker SG: Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:593S-629S.
16. Butchart EG, Payne N, Li HH, et al.: Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002, 123:715-723.
17. Kortke H, Minami K, Breymann T, et al.: [INR self-management after mechanical heart valve replacement: ESCAT (Early Self- Controlled Anticoagulation Trial)]. Z Kardiol 2001, 90(Suppl 6):118-124.
18. Koertke H, Zittermann A, Wagner O, Koerfer R: Selfmanagement of oral anticoagulation therapy improves long-term survival in patients with mechanical heart valve replacement. Ann Thorac Surg 2007, 83:24-29. This is a key trial demonstrating the impact of INR self-management on clinical outcomes among patients with mechanical prosthetic heart valves.
19. Sawicki PT: A structured teaching and self-management program for patients receiving oral anticoagulation: A randomized controlled trial. Working Group for the Study of Patient Self- Management of Oral Anticoagulation. JAMA 1999, 281:145-150.
20. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al.: Selfmonitoring of oral anticoagulation: A systematic review and metaanalysis. Lancet 2006, 367:404-411.
21. Czer LS, Matloff JM, Chaux A, et al.: The St. Jude valve: Analysis of thromboembolism, warfarin-related hemorrhage, and survival. Am Heart J 1987, 114:389-397.
22. Ribeiro PA, AlZaibag M, Idris M et al.: Antiplatelet drugs and the incidence of thromboembolic complications of the St. Jude Medical aortic prosthesis in patients with rheumatic heart disease. J Thorac Cardiovasc Surg 1986, 91:92-98.
23. Little SH, Massel DR: Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2003, (4):CD003464.
24. Antithrombotic Trialists' Collaboration: Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
25. Patrono C: Aspirin and human platelets: From clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci 1989, 10:453-458.
26. Wahl MJ: Dental surgery in anticoagulated patients. Arch Intern Med 1998, 158:1610-1616.
27. Ferreira I, Dos L, Tornos P, et al.: Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003, 89:527-530.
28. Kovacs MJ, Kearon C, Rodger M, et al.: Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004, 110:1658-1663.
29. Brenner B: Haemostatic changes in pregnancy. Thromb Res 2004, 114:409-414.
30. Comp PC, Thurnau GR, Welsh J, Esmon CT: Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986, 68:881-885.
31. Chan WS, Anand S, Ginsberg JS: Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature. Arch Intern Med 2000, 160:191-196.
32. Elkayam U, Bitar F: Valvular heart disease and pregnancy: Part II:prosthetic valves. J Am Coll Cardiol 2005, 46:403-410. (Pubitemid 41040278)
33. Ginsberg JS, Hirsh J, Turner DC, et al.: Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989, 61:197-203. (Pubitemid 19124388)
34. Hall JG, Pauli RM, Wilson KM: Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980, 68:122-140.
35. Douketis JD, Ginsberg JS, Burrows RF, et al.: The effects of longterm heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996, 75:254-257.
36. Warkentin TE, Levine MN, Hirsh J, et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
37. Harenberg J, Schneider D, Heilmann L, Wolf H: Lack of antifactor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 1993, 23:314-320.
38. Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997, 337:688-698.
39. Berndt N, Khan I, Gallo R: A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report. J Heart Valve Dis 2000, 9:844-846.
40. Lev-Ran O, Kramer A, Gurevitch J, et al.: Low-molecular-weight heparin for prosthetic heart valves: Treatment failure. Ann Thorac Surg 2000, 69:264-265; discussion 265-266.
41. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991, 22:983-988.
42. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867. This is a comprehensive meta-analysis evaluating antithrombotic approaches in AF.
43. Turpie AG: New oral anticoagulants in atrial fibrillation. Eur Heart J 2008, 29:155-165.
44. Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151. This is a landmark trial evaluating a novel oral anticoagulant in AF.
45. Lassen MR, Davidson BL, Gallus A, et al.: The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5:2368-2375.